1h Free Analyst Time
The age-related macular degeneration market is forecasted to grow by USD 5.10 bn during 2023-2028, accelerating at a CAGR of 6.54% during the forecast period. The report on the age-related macular degeneration market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by high prevalence of AMD, strong pipeline and expected approvals of AMD therapeutics, and rising geriatric population.
The age-related macular degeneration market is segmented as below:
By Type
- Wet AMD
- Dry AMD
By Distribution Channel
- Hospital pharmacy
- Specialty pharmacy
- Online Pharmacy
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the age-related macular degeneration market covers the following areas:
- Age-related macular degeneration market sizing
- Age-related macular degeneration market forecast
- Age-related macular degeneration market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Type
7 Market Segmentation by Distribution Channel
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
List of Exhibits
Executive Summary
The publisher recognizes the following companies as the key players in the global age-related macular degeneration market: AbbVie Inc., Adverum Biotechnologies Inc., Alimera Sciences Inc., Alkeus Pharmaceuticals Inc., Amgen Inc., Apellis Pharmaceuticals Inc., Bausch Health Companies Inc., Bayer AG, Bio Thera Bio Pharmaceutical Co. Ltd., Biocon Ltd., F. Hoffmann La Roche Ltd., IVERIC bio Inc., Lupin Ltd., Novartis AG, Outlook Therapeutics Inc., Pfizer Inc., Regeneron Pharmaceuticals Inc., Ribomic Inc., Viatris Inc., and Xbrane Biopharma AB.Commenting on the report, an analyst from the research team said: 'The latest trend gaining momentum in the market is strategic alliances by vendors to treat AMD.'
According to the report, one of the major drivers for this market is the high prevalence of AMD.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc.
- Adverum Biotechnologies Inc.
- Alimera Sciences Inc.
- Alkeus Pharmaceuticals Inc.
- Amgen Inc.
- Apellis Pharmaceuticals Inc.
- Bausch Health Companies Inc.
- Bayer AG
- Bio Thera Bio Pharmaceutical Co. Ltd.
- Biocon Ltd.
- F. Hoffmann La Roche Ltd.
- IVERIC bio Inc.
- Lupin Ltd.
- Novartis AG
- Outlook Therapeutics Inc.
- Pfizer Inc.
- Regeneron Pharmaceuticals Inc.
- Ribomic Inc.
- Viatris Inc.
- Xbrane Biopharma AB
